Pharmacogenetic predictors of development of secondary to enalapril dry cough in hypertensive patients

Ivan V. Sychev; Natalia P. Denisenko; Anastasiya A. Kachanova; Anna V. Lapshtaeva; Ludmila N. Goncharova; Karin B. Mirzaev; Dmitry A. Sychev

doi:10.1515/dmpt-2023-0008

Article

Pharmacogenetic predictors of development of secondary to enalapril dry cough in hypertensive patients

Ivan V. Sychev , Natalia P. Denisenko , Anastasiya A. Kachanova , Anna V. Lapshtaeva , Ludmila N. Goncharova , Karin B. Mirzaev and Dmitry A. Sychev

Published/Copyright: May 19, 2023

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information

From the journal Drug Metabolism and Personalized Therapy Volume 38 Issue 3

Abstract

Objectives

Development of the secondary to ACEI cough leads to discontinuation of the drugs of this group. Assessing the safety of the ACEIs with further development of customized approaches for their administration is a major scientific and practical problem. The objective of this study was to assess the association of the genetic markers with the development of the adverse drug reaction in the form of secondary to enalapril dry cough in the patients with essential arterial hypertension.

Methods

Study involved 113 patients with the secondary to enalapril cough and 104 patients without development of the secondary to enalapril adverse drug reaction.

Results

The patients carriers of the genotype AA rs2306283 of gene SLCO1B1 had 2-fold higher odds of developing the dry cough than those with the genotypes AG and GG (ОR=2.01, 95%CI=1.10–3.66, р=0.023). Similarly, the patients heterozygous for rs8176746 of gene АВО had 2.3-fold higher odds of developing the ADR in the form of dry cough than the carriers of the genotypes GG and TT (ОR=2.30, 95%CI=1.24–4.29, р=0.008).

Conclusions

Statistically significant association between the development of the ADR in the form of secondary to enalapril dry cough and polymorphisms rs2306283 of gene SLCO1B1 and rs8176746 of gene ABO was revealed.

Keywords: ACE inhibitors; adverse drug reaction; dry cough; enalapril; hypertensive disease

Corresponding author: Ivan V. Sychev, Postgraduate student, Department of Faculty Therapy with Courses of Physiotherapy, Physical Therapy, Ogarev Mordovia State University, Saransk, Russian Federation; and 68, Bolshevitskaya Street, Saransk, Republic of Mordovia, 430005, Russia, E-mail: sychev_iv@bk.ru

Research funding: The work was performed as part of the Russian Federation Ministry of Health state assignment for the years 2021–2023, no. 121110800062-6 “New Pharmacogenetic Biomarkers of Safety of Pharmacotherapy for Certain Socially Significant Diseases”. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: The study complied with the requirements of the World Medical Association’s Declaration of Helsinki and was approved by the Local Ethics Committee of the Ogarev Mordovia State University (Protocol No. 91 of 12/23/2020).

References

1. Chan, N, Soliman, A. Angiotensin converting enzyme inhibitor‐related angioedema: onset, presentation, and management. Ann Otol Rhinol Laryngol 2015;124:89–96. https://doi.org/10.1177/0003489414543069.Search in Google Scholar PubMed

2. Soo Hoo, G, Lin, H, Junaid, I, Klaustermeyer, W. Angiotensin-converting enzyme inhibitor angioedema requiring admission to an intensive care unit. Am J Med 2015;128:785–9. https://doi.org/10.1016/j.amjmed.2015.02.006.Search in Google Scholar PubMed

3. Yılmaz, İ. Angiotensin-converting enzyme inhibitors induce cough. Turk Thorac J 2019;20:36–42. https://doi.org/10.5152/turkthoracj.2018.18014.Search in Google Scholar PubMed PubMed Central

4. Brugts, J. Discontinuation of angiotensin converting enzyme inhibitors due to dry cough: incidence and clinical determinants. Clin Pharmacol Therapeut 2019;105:563. https://doi.org/10.1002/cpt.1130.Search in Google Scholar PubMed

5. Ng, L, Goh, P. Incidence of discontinuation of angiotensin-converting enzyme inhibitors due to cough, in a primary healthcare centre in Singapore. Singap Med J 2014;55:146–9. https://doi.org/10.11622/smedj.2014034.Search in Google Scholar PubMed PubMed Central

6. Ren, H, Luo, J, Shu, Y, Zhou, H, Zhang, W. Clinical factors and rate of cough during angiotensin-converting enzyme inhibitor treatment. Clin Pharmacol Therapeut 2019;105:566. https://doi.org/10.1002/cpt.1218.Search in Google Scholar PubMed

7. Kobalava, ZD, Konradi, AO, Nedogoda, SV, Shlyakhto, EV, Arutyunov, GP, Baranova, E, et al.. Arterial hypertension in adults. Clinical Guidelines 2020. Russ J Cardiol 2020;25:3786. https://doi.org/10.15829/1560-4071-2020-3-3786.Search in Google Scholar

8. Williams, B, Mancia, G, Spiering, W, Agabiti Rosei, E, Azizi, M, Burnier, M, et al.. 2018 Practice guidelines for the management of arterial hypertension of the European society of hypertension (ESH) and the European society of cardiology (ESC). Blood Pres 2018;27:314–40. https://doi.org/10.1080/08037051.2018.1527177.Search in Google Scholar PubMed

9. Liu, L, Cui, Y, Chung, A, Shitara, Y, Sugiyama, Y, Keppler, D, et al.. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Therapeut 2006;318:395–402. https://doi.org/10.1124/jpet.106.103390.Search in Google Scholar PubMed

10. Mahmoudpour, S, Leusink, M, Putten, L, Terreehorst, I, Asselbergs, F, De Boer, A, et al.. Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis. Pharmacogenomics 2013;14:249–60. https://doi.org/10.2217/pgs.12.206.Search in Google Scholar PubMed

11. Mas, S, Gassò, P, Álvarez, S, Ortiz, J, Sotoca, J, Francino, A, et al.. Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough: the role of ACE, ABO, and BDKRB2 genes. Pharmacogenetics Genom 2011;21:531–8. https://doi.org/10.1097/fpc.0b013e328348c6db.Search in Google Scholar

12. Yamamoto, F, McNeill, P, Hakomori, S. Genomic organization of human histo-blood group ABO genes. Glycobiology 1995;5:51–8. https://doi.org/10.1093/glycob/5.1.51.Search in Google Scholar PubMed

13. Chung, C, Wang, R, Chen, J, Fann, C, Leu, H, Ho, H, et al.. A genome-wide association study identifies new loci for ACE activity: potential implications for response to ACE inhibitor. Pharmacogenomics J 2010;10:537–44. https://doi.org/10.1038/tpj.2009.70.Search in Google Scholar PubMed

14. Fox, A, Lalloo, U, Belvisi, M, Bernareggi, M, Chung, K, Barnes, P. Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough. Nat Med 1996;2:814–7. https://doi.org/10.1038/nm0796-814.Search in Google Scholar PubMed

15. Shen, J, Zhang, D, Fu, Y, Chen, A, Yang, X, Zhang, H. Cryo-EM structures of human bradykinin receptor-Gq proteins complexes. Nat Commun 2022;13:714. https://doi.org/10.1038/s41467-022-28399-1.Search in Google Scholar PubMed PubMed Central

16. Akhmanova, A, Hoogenraad, C, Drabek, K, Stepanova, T, Dortland, B, Verkerk, T, et al.. CLASPs are CLIP-115 and -170 associating proteins involved in the regional regulation of microtubule dynamics in motile fibroblasts. Cell 2001;104:923–35. https://doi.org/10.1016/s0092-8674(01)00288-4.Search in Google Scholar PubMed

17. Luo, J, He, F, Wang, Z, Sun, N, Wang, L, Tang, G, et al.. SLCO1B1 variants and angiotensin converting enzyme inhibitor (Enalapril)-Induced cough: a pharmacogenetic study. Sci Rep 2015;5:1–8. https://doi.org/10.1038/srep17253.Search in Google Scholar PubMed PubMed Central

18. Luo, J, He, F, Lou, Z, Wen, J, Wang, L, Sun, N, et al.. Rs495828 polymorphism of the ABO gene is a predictor of enalapril-induced cough in Chinese patients with essential hypertension. Pharmacogenetics Genom 2014;24:306–13. https://doi.org/10.1097/fpc.0000000000000050.Search in Google Scholar PubMed

19. Mukae, S, Itoh, S, Aoki, S, Iwata, T, Nishio, K, Sato, R, et al.. Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough. J Hum Hypertens 2002;16:857–63. https://doi.org/10.1038/sj.jhh.1001486.Search in Google Scholar PubMed

20. Mahmoudian, M, Mojaverian, N. Effect of noscapine, the antitussive opioid alkaloid, on bradykinin-induced smooth muscle contraction in the isolated ileum of the Guinea-pig. Acta Physiol Hung 2001;88:231–7. https://doi.org/10.1556/aphysiol.88.2001.3-4.5.Search in Google Scholar

21. Mooraki, A, Jenabi, A, Jabbari, M, Zolfaghari, M, Javanmardi, S, Mahmoudian, M, et al.. Noscapine suppresses angiotensin converting enzyme inhibitors-induced cough. Nephrology 2005;10:348–50. https://doi.org/10.1111/j.1440-1797.2005.00429.x.Search in Google Scholar PubMed

22. Hallberg, P, Persson, M, Axelsson, T, Cavalli, M, Norling, P, Johansson, H, et al.. Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population. Pharmacogenomics 2017;18:201–13. https://doi.org/10.2217/pgs-2016-0184.Search in Google Scholar PubMed

Received: 2023-01-07

Accepted: 2023-03-25

Published Online: 2023-05-19

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/dmpt-2023-0008

Keywords for this article

ACE inhibitors; adverse drug reaction; dry cough; enalapril; hypertensive disease